Cytokinetics (CYTK) EVP awarded new stock options and RSUs

Rhea-AI Filing Summary

Cytokinetics executive Andrew Callos received new equity awards as part of his compensation. On March 15, 2026, he was granted 1,665 incentive stock options and 29,480 non-qualified stock options to buy common stock at an exercise price of $60.06 per share, expiring on March 14, 2036.

These stock options vest in 48 equal monthly installments, subject to his continued employment and the company’s Amended and Restated 2004 Equity Incentive Plan. He also received 20,646 restricted stock units as an annual equity award and 13,320 restricted stock units as a special supplemental award, which convert 1:1 into common shares as they vest over one to three years.

Following these awards, Callos directly holds 81,824 shares of common stock. All transactions are coded as awards or acquisitions, with no open-market purchases or sales reported in this filing.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Callos Andrew

(Last) (First) (Middle)

350 OYSTER POINT BLVD

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CYTOKINETICS INC [ CYTK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief Commercial Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/15/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/15/2026		A(1)		20,646	A	$0	68,504	D
Common Stock	03/15/2026		A(2)		13,320	A	$0	81,824	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Incentive Stock Option (Right to Buy)	$60.06	03/15/2026		A(3)		1,665		04/15/2026	03/14/2036	Common Stock	1,665	$0	1,665	D
Non-Qualified Stock Option (Right to Buy)	$60.06	03/15/2026		A(4)		29,480		04/15/2026	03/14/2036	Common Stock	29,480	$0	29,480	D

Explanation of Responses:

1. Annual equity award comprised of restricted stock units ("RSUs") that convert on a 1:1 basis for shares of our common stock. RSUs vest, subject to the officer's continued employment with the company, as follows: 40% of the RSUs on the 1-year anniversary of the grant date, an additional 40% of the RSUs on the 2-year anniversary of the grant date, and the final 20% of the RSUs on the 3-year anniversary of the grant date. RSUs are subject to the company's Amended and Restated 2004 Equity Incentive Plan.

2. Special supplemental equity award comprised of restricted stock units ("RSUs" that convert on a 1:1 basis for shares of our common stock. RSUs vest, subject to the officer's continued employment with the company, as follows: 50% of the RSUs on the 1-year anniversary of the grant date and 50% of the RSUs on the 2-year anniversary of the grant date. RSUs are subject to the company's Amended and Restated 2004 Equity Incentive Plan.

3. Annual equity award comprised of stock options that vest in 48 equal monthly installments, subject to officer's continued employment with the company on each vesting date. Stock options are subject to the company's Amended and Restated 2004 Equity Incentive Plan.

4. Annual equity award comprised of stock options that vest in 48 equal monthly installments, subject to officer's continued employment with the company on each vesting date. Stock options are subject to the company's Amended and Restated 2004 Equity Incentive Plan.

	/s/ John O. Faurescu, attorney-in-fact for Mr. Callos	03/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What equity awards did Cytokinetics (CYTK) EVP Andrew Callos receive?

Andrew Callos received new stock options and restricted stock units as compensation. He was granted 1,665 incentive options, 29,480 non-qualified options at $60.06, plus 20,646 annual RSUs and 13,320 supplemental RSUs, all subject to vesting and continued employment.

How do Andrew Callos’s new stock options at Cytokinetics (CYTK) vest?

The stock options granted to Andrew Callos vest in 48 equal monthly installments. Vesting is conditioned on his continued employment with Cytokinetics and governed by the company’s Amended and Restated 2004 Equity Incentive Plan, with an expiration date of March 14, 2036.

What are the vesting terms for Andrew Callos’s RSU awards at Cytokinetics (CYTK)?

The annual RSU award vests 40% on the first anniversary, 40% on the second, and 20% on the third. The special supplemental RSUs vest 50% on the first anniversary and 50% on the second, all contingent on continued employment under the equity incentive plan.

Did Cytokinetics (CYTK) EVP Andrew Callos buy or sell shares in this Form 4?

No open-market buys or sells were reported. All Form 4 transactions are coded as grants or other acquisitions of stock options and RSUs, representing compensation awards rather than discretionary market purchases or sales of Cytokinetics common stock.

How many Cytokinetics (CYTK) shares does Andrew Callos hold after these awards?

After the reported awards, Andrew Callos directly holds 81,824 shares of Cytokinetics common stock. This figure reflects his updated ownership position following the grants of restricted stock units described in the Form 4 filing.

What is the exercise price and term of Andrew Callos’s Cytokinetics stock options?

Both the incentive and non-qualified stock options have an exercise price of $60.06 per share. They become exercisable starting April 15, 2026, vest monthly over 48 months, and expire on March 14, 2036, assuming continued employment with Cytokinetics.